KFF October 26, 2020
Policy discussions around the potential elimination of the Affordable Care Act (ACA) under the court challenge California v. Texas have largely focused on coverage provisions related to the exchanges, Medicaid and preexisting condition protections. The repeal of the ACA could mean loss of Medicaid coverage for up to 15 million that were enrolled in the ACA Medicaid expansion group prior to the COVID-19 pandemic; however, repeal could also mean significant changes to Medicaid prescription drug policy with implications for state and federal spending for prescription drugs for non-expansion Medicaid enrollees.
Under the Medicaid Drug Rebate Program (MDRP), manufacturers who want their drugs covered by Medicaid must enter a federal rebate agreement under which they rebate a specified portion of the...
Today's Sponsors
Today's Sponsor